Prevalence of the metabolic syndrome in a cohort of HIV infected Nigerian patients on highly active antiretroviral therapy using different using different criteria

Simple item page
dc.contributor.authorIwuala, S.O
dc.contributor.authorFasanmade, O.A
dc.contributor.authorOhwovoriole, A.E
dc.date.accessioned2021-12-01T11:39:08Z
dc.date.available2021-12-01T11:39:08Z
dc.date.issued2008-04
dc.descriptionConference papersen_US
dc.description.abstractBACKGROUND: Highly Active Antiretroviral Therapy (HAART) has been associated with an increased risk of metabolic and fat redistribution abnormalities. Nucleoside Reverse Transcriptase Inhibitor (NRTI)- based regimens, which are the most commonly used in the population under review, are believed to be associated with less risk of these metabolic abnormalities. AIM: The purpose of the study was to compare the prevalence of metabolic syndrome (MS), as defined by the International Diabetes Federation (IDF) criteria and the Adult Treatment Panel III (ATP III) criteria, in a cohort of HAART-treated patients in an ambulatory HIV clinic in Nigeria. METHODS: Data from an ongoing cross-sectional study amongst HAART treated patients were analysed. Information on demographics, HIV infection, medication, personal and family history of cardiovascular risk factors and body fat redistribution was obtained. Physical examination including anthropometry and blood pressure measurement was done. Blood samples for fasting plasma glucose and lipid profile were obtained and analysed according to standard criteria. The prevalence of (MS) defined by the IDF metabolic syndrome consensus definition and the ATP III criteria were compared. The results are presented as mean +/- S.D. Statistical significance was taken as p < 0.05. RESULTS: There were 72 persons studied, 22 (30.6%) males and 50 (69.4%) females. The mean age of the study population was 38.2 +/- 8.1 years and the mean duration of HAART was 2.25 years +/ - 0.99 years. MS was present in 21.9% and 19.4% of the study population using the IDF and the ATP III criteria respectively. MS patients were older (43.6 +/- 10.1 vs 36.8 +/- 6.8 years, p= 0.03) and more likely to be males (37.5% vs 21.9%). CONCLUSION: Metabolic syndrome is seen in about a fifth of HIV patients and may contribute to the high morbidity and mortality from renovascular/ cardiovascular disease in this group of people. The prevalence of the metabolic syndrome was found to be higher using the IDF criteria but the difference was not significant. As with insulin resistance, MS was commoner in males. MS prevalence values were also similar to those from other studies around the world.en_US
dc.identifier.citationIwuala SO, Fasanmade OA, Ohwovoriole AE. Prevalence of the metabolic syndrome in a cohort of HIV infected Nigerian patients on highly active antiretroviral therapy using different using different criteria. Book of abstracts, AACE Nigeria conference 2008en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/9775
dc.language.isoenen_US
dc.publisherNigerian chapter of American Association of Clinical Endocrinologistsen_US
dc.subjectMetabolic syndromeen_US
dc.subjectDiagnostic criteriaen_US
dc.subjectHIVen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectResearch Subject Categories::MEDICINEen_US
dc.titlePrevalence of the metabolic syndrome in a cohort of HIV infected Nigerian patients on highly active antiretroviral therapy using different using different criteriaen_US
dc.typePresentationen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PREVALENCE OF THE METABOLIC SYNDROME IN A COHORT OF HIV 2008 Iwuala abdstract.pdf
Size:
11.93 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine- Conference papers